NetScientific PLC

We have exciting news to share, NetScientific PLC has officially rebranded to EMV Capital plc ($EMVC) from today. This new identity marks a significant milestone in our journey as we continue to evolve and grow. Our rebrand reflects our ongoing commitment to generating superior returns for investors from the fast-growing sectors and technologies that will define our future. As we transition to our new identity, we wanted to let you know that this account will be phased out and will no longer be active. To stay connected and keep up to date with our news and insights please do follow us at EMV Capital plc and visit our website emvcapital.com. The full announcement can be found here https://lnkd.in/dvxNkqz5 and to listen to our CEO, ILIAN ILIEV talk about our rebrand, click here: https://lnkd.in/djb4Y2zH. #VentureCapital #Growth #EMVC #Deeptech #Lifesciences #AIM #EIS #smallcaps

NetScientific reports that its portfolio company, PDS Biotechnology, in which it holds a 3% direct holding, has received the official minutes from its meeting with the FDA regarding next steps in its planned Phase 3 clinical trial of its immunotherapy designed to stimulate a targeted T cell attack against HPV16-positive head and neck squamous cell carcinoma. Read the full announcement: https://lnkd.in/exASYFrX #biotech #biotechnology #immunotherapy #lifesciences

NetScientific announces that all resolutions set out in the 2024 Notice of Annual General Meeting sent to shareholders were duly passed at the Company's Annual General Meeting held earlier today. View the full announcement: https://lnkd.in/gfvZHnNW #aim #smallcap #smallcapstocks #deeptech #lifesciences

Is it time to bring the private equity model to venture capital funding? VC investors range from completely hands-off to ‘venture builders’ who look to add as much value as possible into their portfolio. Dr ILIAN ILIEV, CEO of NetScientific PLC - incorporating the company he founded, EMV Capital - has his feet firmly planted in the latter camp. He explains how its PE-style "value creation services" are bringing in revenues and helping it to become autonomous, while building up the assets in its portfolio. NetScientific recently acquired the operational VC business of Cambridge-based Martlet Capital – excluding the Martlet portfolio – in a non-dilutive transaction which increased assets under management by 89% to over £100m 🚀 https://lnkd.in/d7TCt6Rr

In this interview with Vox Markets, Dr ILIAN ILIEV, CEO of NetScientific, discusses a milestone year which saw it reach a significant milestone of managing £100m in assets, a substantial increase from £8m in 2020. Dr Iliev highlights the company’s capital-efficient investment strategy, which involves using a mix of its own funds and syndicated investments from third-party investors, and its value creation services, which involve actively engaging with portfolio companies to improve their strategies and operations. Learn more ⬇ #aim #smallcap #smallcapstocks #deeptech #lifesciences

NetScientific featured in Investors' Chronicle following the release of its annual results. Simon Thompson highlights: ''NetScientific has been making eye-catching progress in the past year even if it has yet to be reflected in the Aim-traded investment company’s share price.'' #investment #venturecapital #lifesciences #smallcap #aim

NetScientific announces that its Annual General Meeting will be held on Wednesday, 10 July 2024 at 10:00 a.m. at Panmure Gordon, Ropemaker Place, Level 12, 25 Ropemaker Street, London EC2Y 9LY.   Read the full announcement: https://lnkd.in/eADGws5G #aim #smallcap #smallcapstocks #deeptech #lifesciences

Panmure Gordon has initiated coverage on NetScientific PLC (AIM:NSCI) with a 'buy' recommendation and a price target of 137 pence, hailing its shift away from traditional venture capital (VC) investment models towards a focus on deep technology and life sciences sectors. NetScientific, under the leadership of CEO Dr Ilian Iliev since 2020, has evolved to support innovation and growth in these sectors, the broker said. More at #Proactive #ProactiveInvestors http://ow.ly/JGQm105x6MC

Dr ILIAN ILIEV, NetScientific CEO, joins Proactive with details of the company’s achievements in 2023 and its future goals. Dr Iliev highlights NetScientific's strong portfolio and significant revenue growth, having successfully raised c.£60m for its portfolio companies. The company's AUM increased to over £100m, which represents a significant leap from just £8m three years ago. He also explains the company’s strategy of building a resilient VC platform focused on deep tech and life sciences, enhanced by the addition of a fund management function to scale the capital available to portfolio companies. Watch the full interview ⬇ #aim #venturecapital #deeptech #lifesciences #smallcap

NetScientific is pleased to announce its preliminary results for the year ended 31 December 2023. We have made good progress on consolidating our position, protecting our portfolio with some notable successes, in a difficult market environment. Highlights include: 🔹 Total Assets Under Management of £74m at year end and £100m+ post balance sheet 🔹 Fair value of managed and third-party holdings increased by c.42% to £38.4m 🔹 13 portfolio companies raised an aggregate amount of £53.9m, including EMV Capital syndicated investments of c.£6.2m 🔹 Portfolio has increased to 70+ companies post balance sheet date 🔹 Group income increased to £3.8m, with EMV Capital revenue increasing by c.40% to £1.6m 🔹 Partial exits of c.£1.4m through secondary market sales across two portfolio companies Dr ILIAN ILIEV, CEO of NetScientific, commented: "2023 has been another year of progress, proactively funding, defending and developing the value of our portfolio whilst continuing to build a sustainable platform to realise our goal of becoming a leading VC investor in the deep tech and life sciences sectors in the UK and internationally. Our AUM passing an important £100 million milestone is testament to the groundwork of 2023, and we look forward to progressing towards the next milestone of £200 million AUM through driving the organic growth of our existing portfolio, now in excess of 70 companies, and other initiatives underway to expand our funds practice." View the full announcement: https://lnkd.in/eZp6naWf #aim #smallcap #smallcapstocks #deeptech #lifesciences